575 related articles for article (PubMed ID: 1501713)
21. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.
Hazbón MH; Brimacombe M; Bobadilla del Valle M; Cavatore M; Guerrero MI; Varma-Basil M; Billman-Jacobe H; Lavender C; Fyfe J; García-García L; León CI; Bose M; Chaves F; Murray M; Eisenach KD; Sifuentes-Osornio J; Cave MD; Ponce de León A; Alland D
Antimicrob Agents Chemother; 2006 Aug; 50(8):2640-9. PubMed ID: 16870753
[TBL] [Abstract][Full Text] [Related]
22. The mechanism of isoniazid killing: clarity through the scope of genetics.
Vilchèze C; Jacobs WR
Annu Rev Microbiol; 2007; 61():35-50. PubMed ID: 18035606
[TBL] [Abstract][Full Text] [Related]
23. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.
Almeida Da Silva PE; Palomino JC
J Antimicrob Chemother; 2011 Jul; 66(7):1417-30. PubMed ID: 21558086
[TBL] [Abstract][Full Text] [Related]
24. Crystal structure of Mycobacterium tuberculosis catalase-peroxidase.
Bertrand T; Eady NA; Jones JN; Jesmin ; Nagy JM; Jamart-Grégoire B; Raven EL; Brown KA
J Biol Chem; 2004 Sep; 279(37):38991-9. PubMed ID: 15231843
[TBL] [Abstract][Full Text] [Related]
25. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities.
Vilchèze C; Jacobs WR
Microbiol Spectr; 2014 Aug; 2(4):MGM2-0014-2013. PubMed ID: 26104204
[TBL] [Abstract][Full Text] [Related]
26. Role of KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte oxidative burst.
Ng VH; Cox JS; Sousa AO; MacMicking JD; McKinney JD
Mol Microbiol; 2004 Jun; 52(5):1291-302. PubMed ID: 15165233
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015.
Zhang Y; Yew WW
Int J Tuberc Lung Dis; 2015 Nov; 19(11):1276-89. PubMed ID: 26467578
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.
Mdluli K; Slayden RA; Zhu Y; Ramaswamy S; Pan X; Mead D; Crane DD; Musser JM; Barry CE
Science; 1998 Jun; 280(5369):1607-10. PubMed ID: 9616124
[TBL] [Abstract][Full Text] [Related]
29. The mutations of katG and inhA genes of isoniazid-resistant Mycobacterium tuberculosis isolates in Taiwan.
Tseng ST; Tai CH; Li CR; Lin CF; Shi ZY
J Microbiol Immunol Infect; 2015 Jun; 48(3):249-55. PubMed ID: 24184004
[TBL] [Abstract][Full Text] [Related]
30. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA.
Guo H; Seet Q; Denkin S; Parsons L; Zhang Y
J Med Microbiol; 2006 Nov; 55(Pt 11):1527-1531. PubMed ID: 17030912
[TBL] [Abstract][Full Text] [Related]
31. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.
Vilchèze C; Wang F; Arai M; Hazbón MH; Colangeli R; Kremer L; Weisbrod TR; Alland D; Sacchettini JC; Jacobs WR
Nat Med; 2006 Sep; 12(9):1027-9. PubMed ID: 16906155
[TBL] [Abstract][Full Text] [Related]
32. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.
Unissa AN; Subbian S; Hanna LE; Selvakumar N
Infect Genet Evol; 2016 Nov; 45():474-492. PubMed ID: 27612406
[TBL] [Abstract][Full Text] [Related]
33. Regulation of NFATc1 in Osteoclast Differentiation.
Kim JH; Kim N
J Bone Metab; 2014 Nov; 21(4):233-41. PubMed ID: 25489571
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis.
Blanchard JS
Annu Rev Biochem; 1996; 65():215-39. PubMed ID: 8811179
[TBL] [Abstract][Full Text] [Related]
35. Isoniazid: an update on the multiple mechanisms for a singular action.
Bernardes-Génisson V; Deraeve C; Chollet A; Bernadou J; Pratviel G
Curr Med Chem; 2013; 20(35):4370-85. PubMed ID: 23931278
[TBL] [Abstract][Full Text] [Related]
36. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol.
Telenti A; Philipp WJ; Sreevatsan S; Bernasconi C; Stockbauer KE; Wieles B; Musser JM; Jacobs WR
Nat Med; 1997 May; 3(5):567-70. PubMed ID: 9142129
[TBL] [Abstract][Full Text] [Related]
37. Rasburicase for the treatment of tumor lysis in hematological malignancies.
Malaguarnera G; Giordano M; Malaguarnera M
Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
[TBL] [Abstract][Full Text] [Related]
38. New pathophysiological concepts underlying pathogenesis of pigment gallstones.
Vítek L; Carey MC
Clin Res Hepatol Gastroenterol; 2012 Apr; 36(2):122-9. PubMed ID: 21978438
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.
Bouguen G; Chevaux JB; Peyrin-Biroulet L
World J Gastroenterol; 2011 Feb; 17(5):547-56. PubMed ID: 21350703
[TBL] [Abstract][Full Text] [Related]
40. Role of cytokines in inflammatory bowel disease.
Sanchez-Munoz F; Dominguez-Lopez A; Yamamoto-Furusho JK
World J Gastroenterol; 2008 Jul; 14(27):4280-8. PubMed ID: 18666314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
